Genmab — Februar 2019
-
Du er sikker på, at det ikke var den resulterende rødvin, der skabte problemerne?
-
where do you think we are on that RTOR timeline? i saw earlier in this onclive article "Janssen and Genmab have completed the first part of a supplemental biologics license application for daratumumab …." https://www.onclive.com/web-exclusives/fda-approves-splitdosing-regimen-of-daratumumab-for-multiple-myeloma?p=2
-
According to the timeline first submission takes place 6-9 weeks after top line. That was 3 weeks ago. Lets say week 12 now then. Which means another 4 weeks to last submission. And then another 4 weeks until decision. This is maximum. Could be shorter.
-
Der er lidt baggrund omkring de forskellige godkendelsesprocessen her - https://www.focr.org/sites/default/files/pdf/ROTR White Paper 1.pdf
-
Se specielt side 8 med diagrammer for kisqali og Keytruda rtor processer
-
Men det ser også ud til at fda strammer processen til fra 2018 til 2019, så det bliver noget mere smooth
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind